Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetonitrile SCHEMBL8910586 | 0.95 | MEN1 (0.33) | MEN1KMT2A | |
| Acetonitrile SCHEMBL3477901 | 0.95 | MEN1 (0.33) | MEN1KMT2A | |
| Methyl Alcohol SCHEMBL2652388 | 0.86 | MEN1 (0.38) | MEN1KMT2A | |
| Water SCHEMBL1251556 | 0.83 | MEN1 (0.40) | MEN1KMT2A | |
| Alcohol SCHEMBL5066648 | 0.80 | TSHR (0.38) | MEN1KMT2A | |
| SCHEMBL5544690 | 0.80 | MEN1 (0.42) | MEN1KMT2A | |
| SCHEMBL7097725 | 0.80 | — | — | |
| SCHEMBL1746 | 0.80 | — | — | |
| SCHEMBL28199597 | 0.79 | ALDH1A1 (0.33) | MEN1KMT2A | |
| Methylene Chloride SCHEMBL951080 | 0.78 | MEN1 (0.46) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385039-B1 | 2-Iminoisoindolinone derivatives as thrombin receptor antagonists | EISAI R&D MAN CO LTD (JP) | 2014-03-12 | — | — | EP | disclosed |
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-2385039-A1 | 2-Iminoisoindolinone derivatives as thrombin receptor antagonists | Eisai R&D Management Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20090215795-A1 | CYCLIC AMIDINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1391456-B1 | 2-IMINOIMIDAZOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-1386912-B1 | CYCLIC AMIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-7476688-B2 | Cyclic amidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-13 | — | — | US | disclosed |
| CN-100402499-C | 2-iminopyrrolidine derivatives | EISAI CO LTD (JP) | 2008-07-16 | — | — | CN | disclosed |
| US-7304083-B2 | 2-iminoimidazole derivatives (2) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| EP-1614680-A2 | Process for preparing 2-iminopyrrolidine derivatives | Eisai Co., Ltd. (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004197-A1 | 2-iminoimidazole derivatives (2) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-20040254376-A1 | Cyclic amidine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| US-20040242627-A1 | 2-Iminoimidazole derivatives (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| CN-1503784-A | 2-iminopyrrolidine derivatives | ������������ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| EP-1394152-A1 | 2-IMINOIMIDAZOLE DERIVATIVES (1) | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1386912-A1 | CYCLIC AMIDINE DERIVATIVE | Eisai Co., Ltd. (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004197-A1 | 2-iminoimidazole derivatives (2) | H1-2, H1-3, H1-4 | MEN1 581/4885KMT2A 1299/4885 |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | MEN1 891/4885KMT2A 2082/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | MEN1 859/4885KMT2A 2110/4885 |
| US-20040242627-A1 | 2-Iminoimidazole derivatives (1) | H1-2, H1-0, H1-3 | MEN1 1601/4885KMT2A 340/4885 |
| US-20040254376-A1 | Cyclic amidine derivative | ARGLU1, ARG1, PRMT1 | MEN1 302/4885KMT2A 1267/4885 |
| US-20090215795-A1 | CYCLIC AMIDINE DERIVATIVES | H1-10, H1-3, H1-4 | MEN1 169/4885KMT2A 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.